Latest News - Regeneron Pharmaceuticals
Top Corporates Hub
Regeneron Pharmaceuticals
Regeneron (REGN) Enters $2.32B Collaboration With Parabilis to Target ‘Undruggable’ Proteins
25.05.2026 19:54
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the cheap NASDAQ stocks to buy right now. On May 19, Regeneron Pharmaceuticals entered into a $2.32 billion research collaboration with Parabilis Medicines to develop therapeutic candidates using Parabilis’ Helicon peptide platform. The partnership will focus on creating Helicons (stabilized, cell-penetrant alpha-helical peptides) that can be used as […]
Regeneron R&D Updates Test Market View On Long Term Pipeline Value
24.05.2026 06:08
Regeneron Pharmaceuticals (NasdaqGS:REGN) reported positive early-stage trial results for Lynozyfic in systemic AL amyloidosis, with high response rates and signs of organ function improvement. The European Medicines Agency accepted Otarmeni, a gene therapy candidate for OTOF-related hearing loss, for accelerated review as a potential first treatment of its kind in Europe. These twin updates arrive at a time when NasdaqGS:REGN is trading at $638.88, with the stock down 8.5% over the past...
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
22.05.2026 11:00
TARRYTOWN, N.Y., May 22, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency (EMA) has accepted for review under Accelerated Assessment the Marketing Authorization Application (MAA) for Otarmeni™ (lunsotogene parvec), an in vivo adeno-associated virus vector-based gene therapy for the treatment of biallelic OTOF variant-associated hearing loss. Otarmeni, formerly known as DB-OTO, previously received Orphan Designation from the EMA
Jim Cramer on Regeneron: “There Could Be Some More Downgrades”
21.05.2026 13:12
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was among the stocks Jim Cramer discussed while explaining how investors can navigate the current market rotation. Cramer highlighted the company’s unsuccessful trial, as he remarked: Finally, there’s Regeneron, which got blasted by a poor result on a metastatic melanoma cancer trial. I, along with many others, thought that this trial […]
Apogee Therapeutics: Targeting Atopic Dermatitis
21.05.2026 11:53
Apogee Therapeutics, Inc. is rated a Hold, driven by promising data for the lead asset zumilokibart in atopic dermatitis. Read more on APGE stock here.
ATS 2026: Mixed results for Sanofi/Regeneron’s itepekimab cloud COPD prospects
20.05.2026 17:54
Failure of AERIFY-2 to show clear benefit in COPD places itepekimab on the backfoot against AstraZeneca’s tozorakimab.
After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets
20.05.2026 11:58
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in total proceeds.
Why Regeneron Pharmaceuticals (REGN) Is Down 11.7% After Key Melanoma Combo Trial Missed Its Goal
19.05.2026 12:11
Earlier in May 2026, Regeneron Pharmaceuticals reported that its Phase 3 trial of fianlimab plus cemiplimab in first-line unresectable or metastatic melanoma failed to achieve statistically significant improvement in progression-free survival versus pembrolizumab, although no new safety issues emerged. This trial miss has already prompted legal scrutiny of Regeneron’s leadership and intensified concerns about the company’s oncology pipeline and future revenue mix. We’ll now examine how...
Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates
19.05.2026 10:16
Parabilis is set to receive $125m, including a $50m upfront payment and a $75m investment, subject to agreed conditions.
3 Reasons to Sell REGN and 1 Stock to Buy Instead
18.05.2026 01:00
Regeneron has been treading water for the past six months, recording a small return of 3.4% while holding steady at $717.22. The stock also fell short of the S&P 500’s 9.9% gain during that period.
3 Reasons to Sell REGN and 1 Stock to Buy Instead
18.05.2026 01:00
Regeneron has been treading water for the past six months, recording a small return of 3.4% while holding steady at $717.22. The stock also fell short of the S&P 500’s 9.9% gain during that period.
Regeneron Pharmaceuticals Provides Update on Phase 3 Trial of Fianlimab Combination in First-Line Unresectable or Metastatic Melanoma
16.05.2026 08:51
Regeneron Pharmaceuticals, Inc. reviewed results from the Phase 3 trial evaluating two dose levels of fianlimab in combination with cemiplimab as a first-line treatment for patients with...
Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
16.05.2026 00:19
The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement of 5.1 months in median PFS was observed for the high-dose fianlimab combination compared to pembrolizumab monotherapy Phase 3 head-to-head trial of the high-dose fianlimab combination versus Opdualag® (nivolumab and relatlimab-rmbw) is ongoing TARRYTOWN, N.Y., May 15, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today review
Is Regeneron Pharmaceuticals (REGN) Among the Best Biotech Stocks to Invest In According to Billionaire Steve Cohen?
12.05.2026 00:04
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the Best Biotech Stocks. On April 23, Reuters reported that the U.S. Food and Drug Administration approved Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s gene treatment for a rare genetic form of deafness. It is the first gene therapy for genetic hearing loss. The firm stated that the therapy, Otarmeni, will be given […]
Is Regeneron Pharmaceuticals (REGN) Among the Best Biotech Stocks to Invest In According to Billionaire Steve Cohen?
12.05.2026 00:04
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the Best Biotech Stocks. On April 23, Reuters reported that the U.S. Food and Drug Administration approved Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s gene treatment for a rare genetic form of deafness. It is the first gene therapy for genetic hearing loss. The firm stated that the therapy, Otarmeni, will be given […]
Dr. Scott Gottlieb: Could see more hantavirus case, but don't think it will get out of control
11.05.2026 08:31
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the state of the hantavirus outbreak, risk of a wider outbreak, fate of FDA Commissioner Marty Makary, FDA's new flavored vape policy, and more.
Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years
08.05.2026 11:00
Regeneron also earns spot on Dow Jones Best-in-Class North America Index for six consecutive years Recognition complements the company’s recent announcement that it will provide its new gene therapy for a form of genetic hearing loss for free in the United States, reinforcing its commitment to patient access New science-led 2030 responsibility goals reflect Regeneron’s commitment to corporate responsibility, from how it innovates to how it operates, for the good of its business and humanity TARR
Is This Biotech Stock a Buy After a Groundbreaking Approval?
08.05.2026 08:05
This milestone came with an asterisk.
Trump’s Affordability Push Stalls Ahead of Midterm Elections
07.05.2026 10:45
(Bloomberg) -- The Trump administration’s fitful campaign to address US voters’ affordability concerns ahead of the midterm elections is faltering, with some key efforts stalled, cast aside or limited in scope. Most Read from BloombergUS Has Opened a Passage Through Hormuz, Central Command SaysDOJ Plans Intervention in Trump Supreme Court Carroll AppealUS Says Offensive Phase of Iran War Over as Ship Hit in StraitSony to Pay Almost $4 Billion for Bieber, Neil Young CatalogChina Asks Banks to Pau
RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect
06.05.2026 16:00
Ultragenyx posts a wider-than-expected Q1 loss as Crysvita sales fall on seasonal effects, while Evkeeza and Dojolvi revenue growth partially offset declines.